A 52-week Italian real-world study reported that upadacitinib kept moderate-to-severe atopic dermatitis controlled for most patients, with outcomes described in terms of average equivalent days in control during the first year. The dataset complements pivotal trial results by describing durability of effect outside tightly controlled protocols. In another routine-care readout, a Phase IV Indian heart failure study reported high achievement of the vericiguat 10 mg target dose in worsening heart failure patients with no new safety signals. Together, the updates support continued scrutiny of long-term dosing behavior and tolerability in heterogeneous patient populations.